Association Between Post-Transplant Donor Specific Antibodies and Recipient Outcomes in Simultaneous Liver-Kidney Transplant Recipients: single center, cohort study.
There is a dearth of published data regarding the presence of post-transplant Donor Specific Antibodies(DSA), especially C1q binding DSA(C1q+DSA), and patient and kidney allograft outcomes in simultaneous liver-kidney transplant(SLKT) recipients. We conducted a retrospective cohort study consisted of 85 consecutive SLKT patients between 2009-2018 in our center. Associations between presence of post-transplant DSA, including persistent and/or newly developed DSA and C1q+DSA, and all-cause mortality and the composite outcome of mortality, allograft kidney loss, and antibody-mediated rejection were examined using unadjusted and age and sex-adjusted Cox proportional hazards regression models. The mean age at SLKT was 56 years and 60% of the patients were male. Twelve patients(14%) had post-transplant DSA and 7 patients (8%) had C1q+DSA. The presence of post-transplant DSA was significantly associated with increased risk of mortality (unadjusted model: Hazard Ratio (HR)=2.72, 95%Confidence Interval(CI):1.06-6.98 and adjusted model: HR=3.20, 95%CI:1.11-9.22) and the composite outcome (unadjusted model: HR=3.18, 95%CI: 1.31-7.68 and adjusted model: HR=3.93, 95%CI:1.39-11.10). There was a trend towards higher risk for composite outcome in recipients with C1q+DSA compared the ones without C1q+DSA. Post-transplant DSA is significantly associated with worse patient and kidney allograft outcomes in SLKT. Further prospective and large cohort studies are warranted to better assess these associations.